Court Denies Sandoz/Momenta's Summary Judgment of Invalidity in Copaxone® Litigation
Teva Pharmaceutical Industries Ltd. On Tuesday September 7, 2010, 1:21 pm
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA - News) announced today that the U.S. District Court for the Southern District of New York has denied a motion for summary judgment filed by Sandoz Inc./Momenta Pharmaceuticals, Inc., that the patents at issue are invalid for indefiniteness. The court has not yet set a trial date.
Richard Egosi, Corporate Vice President and Chief Legal Officer commented: "Teva is very pleased with today's decision, which reaffirms our belief that the patents are valid and enforceable. We remain committed to vigorously defending Copaxone® IP rights against infringement wherever they are challenged."
About Teva
Market Data 
Markets 
AI
